--- title: "Biotech stock winners and losers this week" url: "https://aibio.space/winners-losers/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "The biotech stocks with the biggest reported moves, up and down, and the news behind each one: takeovers, trial results, IPO debuts and financings." --- Tracker # Biotech winners and losers The biotech stocks with the biggest reported moves, up and down, and the news behind each one: takeovers, trial results, IPO debuts and financings. Moves as reported on the dates shown, as of October 23, 2026. Each line comes from a fact-checked story or the company's own release. [All trackers](https://aibio.space/trackers/). ## Biggest gainers | Date | Company | Move | Why | |---|---|---|---| | Oct 19 | [Silence Therapeutics](https://aibio.space/companies/silence-therapeutics/) SLN | +130% | Merck KGaA offers $20 per ADS in cash, a 130% premium to the Oct. 16 close. [Our story](https://aibio.space/news/merck-kgaa-agrees-buy-silence-therapeutics-20-ads-get-pv-drug/) | | Oct 16 | [City Therapeutics](https://aibio.space/companies/city-therapeutics/) CTY | +28% | Opened at $23 on its Nasdaq debut after an upsized $200 million IPO priced at $18. [Our story](https://aibio.space/news/city-therapeutics-raises-200-million-upsized-ipo-priced-18/) | | Oct 20 | [Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON | $450M | Upsized raise at $75 a share, one day after a positive phase 3 result. [Our story](https://aibio.space/news/disc-medicine-raises-450-million-75-share-after-phase-3-win/) | | Oct 9 | [Vaxcyte](https://aibio.space/companies/vaxcyte/) PCVX | $1.1B | Raised about $1.1 billion at $64 a share and a 1.50% convertible, after a phase 3 win. [Our story](https://aibio.space/news/vaxcyte-raises-about-1-1-billion-stock-convertible-notes-after-phase-3/) | | Sep 24 | [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) VKTX | +45% | Sold $259 million of 2% converts at a 45% conversion premium, plus stock at $35, after maintenance data. [Our story](https://aibio.space/news/viking-raises-575-million-stock-convertible-notes-after-maintenance/) | | | [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) AKTS | | IPO upsized, raises about $318M at $18 [Our story](https://aibio.space/news/aktis-oncology-prices-upsized-ipo-18-raising-about-318-million/) | | | [Alumis](https://aibio.space/companies/alumis/) ALMS | | Raises $300M after psoriasis pill wins phase 3 [Our story](https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/) | | | [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) GLUE | | Upsizes stock sale to $300M after NEK7 data [Our story](https://aibio.space/news/monte-rosa-upsizes-stock-sale-300-million-after-oral-nek7-degrader/) | | | [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR | | Authorizes another $2B share buyback [Our story](https://aibio.space/news/united-therapeutics-authorizes-another-2-billion-share-repurchase/) | | | [Ultragenyx](https://aibio.space/companies/ultragenyx-pharmaceutical/) RARE | | Sells two priority review vouchers for $413M [Our story](https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/) | | | [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) PTGX | | $300M buyback after two drug approvals [Our story](https://aibio.space/news/protagonist-authorizes-300-million-share-buyback-after-two-drug/) | | | [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX | | Closes $345M raise, funded through 2028 [Our story](https://aibio.space/news/celldex-closes-345-million-raise-guides-funding-through-2028/) | ## Biggest losers | Date | Company | Move | Why | |---|---|---|---| | Oct 19 | [EyePoint](https://aibio.space/companies/eyepoint/) EYPT | -80% | Shares fell more than 80% at the open to 55 cents after a second Duravyu wet AMD phase 3 miss. [Our story](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/) | | Oct 16 | [Fractyl Health](https://aibio.space/companies/fractyl-health/) GUTS | -48% | Shares fell about 48% to around $2.14 even though Revita met its six-month endpoint. [Our story](https://aibio.space/news/fractyl-shares-fall-48-percent-even-revita-meets-six-month-remain-1/) | | Aug 31 | [BioAtla](https://aibio.space/companies/bioatla/) BCAB | OTC | Nasdaq upheld its delisting. Trading moved from Nasdaq to the OTC Markets under BCAB on Aug. 31. [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/0001826892/000153949726002373/n5620_x8-8k.htm) | | Sep 19 | [Xenon](https://aibio.space/companies/xenon-pharmaceuticals/) XENE | -26% | Shares fell 26% pre-market to $42.25 from $57.35 after it paused phase 3 depression enrollment. [Our story](https://aibio.space/news/xenon-pauses-depression-trial-enrollment-after-psychosis-reports/) | | Oct 21 | [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) RCUS | -8% | Raised $250 million at $17.50, about 8% below the last sale, after the stock fell about 20% in two days. [Our story](https://aibio.space/news/arcus-raises-250-million-17-50-share-day-after-kidney-cancer-data/) | | | [BioXcel Therapeutics](https://aibio.space/companies/bioxcel-therapeutics-btai/) BTAI | | Files Chapter 11, Teva is stalking horse [Our story](https://aibio.space/news/bioxcel-files-chapter-11-teva-57-5-million-stalking-horse-bidder/) | | | [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) TCRX | | Cuts 75% of staff, pauses phase 3 [Our story](https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/) | | | [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA | | Cuts 72% of staff after failed buyout [Our story](https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/) | | | Sangamo Therapeutics SGMO | | Nasdaq delisting final in Chapter 11 [Our story](https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/) | | | [Senti Biosciences](https://aibio.space/companies/senti-biosciences/) SNTI | | Two Nasdaq notices: bid price and equity [Our story](https://aibio.space/news/senti-biosciences-gets-two-nasdaq-notices-bid-price-3-4m-equity/) | | | [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) CAPR | | New class action and derivative suit [Our story](https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/) | | | [Outlook Therapeutics](https://aibio.space/companies/outlook-therapeutics/) OTLK | | Nasdaq bid-price notice after approval [Our story](https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/) | Reported moves, not a recommendation to buy or sell. [How we work](https://aibio.space/disclosures/). --- Source page: https://aibio.space/winners-losers/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biotech stock winners and losers this week", 2026-10-31, https://aibio.space/winners-losers/